Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review

Cho-Hsun Hsieh · Yi-Wei Huang · Tsen-Fang Tsai

Received: January 31, 2022 / Published online: April 5, 2022 © The Author(s) 2022

ABSTRACT

There is an increasing trend of malignancy worldwide. Disease-modifying antirheumatic drugs (DMARDs) are the cornerstones for the treatment of immune-mediated inflammatory diseases (IMIDs), but risk of malignancy is a major concern for patients receiving DMARDs. In addition, many IMIDs already carry higher background risks of neoplasms. Recently, the black box warning of malignancies has been added for Janus kinase inhibitors. Also, the use of biologic DMARDs in patients with established malignancies is usually discouraged owing to exclusion of such patients in pivotal studies and, hence, lack of evidence. In contrast, some conventional synthetic DMARDs (csDMARDs) have been reported to show antineoplastic properties and can be beneficial for patients with cancer. Among the csDMARDs, chloroquine and hydroxychloroquine have been the most extensively studied, and methotrexate is an established chemotherapeutic agent. Even cyclosporine A, a well-known drug associated with cancer risk, can potentiate the effect of some chemotherapeutic agents. We review the possible mechanisms behind and clinical evidence of the antineoplastic activities of csDMARDs, including chloroquine and hydroxychloroquine, cyclosporine, leflunomide, mycophenolate mofetil, mycophenolic acid, methotrexate, sulfasalazine, and thiopurines. This knowledge may guide physicians in the choice of csDMARDs for patients with concurrent IMIDs and malignancies.

Keywords: DMARDs; Cancer; Chloroquine and hydroxychloroquine; Cyclosporine; Leflunomide; Mycophenolate mofetil; Mycophenolic acid; Methotrexate; Sulfasalazine; Thiopurine
Key Summary Points

- csDMARDs still constitute the cornerstone in the treatment of immune-based inflammatory diseases in the era of biologics.
- The use of biologic DMARDs in patients with established malignancies is usually discouraged owing to lack of evidence.
- Many csDMARDs, especially chloroquine (CQ)/hydroxychloroquine (HCQ) and methotrexate (MTX), have established antineoplastic effects, either alone or in combination with chemotherapeutic agents.
- Knowledge of the antineoplastic potentials of csDMARDs may guide physicians in the choice of csDMARDs for patients with concurrent IMIDs and malignancies.

INTRODUCTION

Disease-modifying antirheumatic drugs (DMARDs) are often referred to as immunosuppressants or immunomodulators. Their antiinflammatory effect improves the symptoms and reduces the damage caused by rheumatic diseases [1]. However, the immunosuppressive property of DMARDs raises concern for the development of malignancy. It is especially important in view of the increasing number of patients with malignancy worldwide, mainly due to the aging population.

DMARDs can be further classified as conventional synthetic (csDMARDs), biologic (bDMARDs), and targeted synthetic [tsDMARDs, e.g., Janus kinase (JAK) inhibitors and phosphodiesterase-4 inhibitors]. csDMARDs are small molecules, for instance, azathioprine (AZA), chloroquine (CQ), hydroxychloroquine (HCQ), cyclosporine A (CSA), mycophenolate mofetil (MMF), mycophenolic acid (MPA), leflunomide, and sulfasalazine (SSZ). bDMARDs are monoclonal antibodies or fusion proteins developed to block specific molecules on immune cells or cytokines (IL-6, IL-1, TNF-α, etc.) [2].

Recently, the US Food and Drug Administration (FDA) issued a black box warning for all JAK inhibitors (https://www.fda.gov/media/151936) regarding their increased risk for malignancies and thrombosis, mainly based on a tofacitinib trial in patients with rheumatoid arthritis [3]. Also, the use of bDMARDs is often discouraged in patients with established malignancies, mainly owing to the exclusion of such patients in pivotal clinical trials and, hence, the lack of evidence for use in such patients. In addition, patients with autoimmune disease, such as psoriasis and rheumatoid arthritis, were shown to have higher malignancy risks [4]. Thus, it is timely to reassess the carcinogenicity and antineoplastic properties of csDMARDs.

The long-term use of some csDMARDs is considered to increase the risk of malignancy [5–10]. However, evidence suggests that some csDMARDs have antineoplastic effects and may be used to treat malignancies. The concept that chronic inflammation is associated with carcinogenesis has been well established [11], and the antiinflammatory effects of csDMARDs may be contributory to their antineoplastic properties. Although the exact antineoplastic mechanisms of csDMARDs remain unknown, some csDMARDs, such as CQ, HCQ, CsA, etc., have already been utilized in cancer management for a long time. This review focuses on csDMARDs reported to have antineoplastic potential in their commonly used dosages as DMARDs.

METHODS

A literature search of the PubMed database was conducted using the keywords (Drug name [MeSH Terms]) AND (Neoplasm [MeSH Terms]), from inception to 20 September 2021. Citation lists of selected articles were used to identify other relevant articles. Afterwards, a two-step search was conducted. First, we identified types of cancer related to a specific csDMARD, and then we used the drug names and the cancer
Specific cancers related identified through PubMed database searching by using keywords “(Drug name [MeSH Terms]) AND (Neoplasm [MeSH Terms])”.

Articles identified through PubMed database searching by using keywords “(Drug name [MeSH Terms]) AND (Specific cancer [MeSH Terms])”.
(e.g., Chloroquine/Hydroxychloroquine AND Colorectal cancer, n = 50)

Articles retrieved. Exclude no abstracts, or keyword not included in title/abstract. (n = 41)

Full-text articles assessed for eligibility. (n = 2)

Additional articles identified from citation lists of selected articles. (n = 0)

Total articles included in this review. (n = 2)

Fig. 1 Flow chart of the article searching strategy. A two-step search was conducted as follows: Step 1: (Drug name [MeSH Terms]) AND (Neoplasm [MeSH Terms]) → identify the specific cancer. Step 2: (Drug name [MeSH Terms]) AND (Specific cancer [MeSH Terms])

RESULTS

DMARDs have been proven to have efficacy in different malignancies through a variety of mechanisms (Tables 1 and 2). For patients with immune-based diseases and malignancies, some oral DMARDs could be the treatment of choice owing to their antineoplastic activity.

Chloroquine and Hydroxychloroquine

CQ and HCQ are 4-aminoquinolines that have been used for malaria treatment. As csDMARDs, they are also indicated for rheumatoid arthritis and systemic lupus erythematosus. Cancer cell survival was found related to autophagy [13, 14], which clears damaged cellular debris delivered to lysosomes. HCQ inhibits autophagy by blocking the fusion of the autophagosome to the lysosome, which may lead to an antineoplastic effect [13, 14].

Reviews

In a nationwide population-based cohort study, patients with autoimmune diseases were enrolled and patient data were collected from Taiwan National Health Insurance Database. After
Table 1  Mechanisms regarding antineoplastic activities of DMARDs

| Medication     | Proposed antineoplastic mechanism                                                                 | Preclinical study | Malignancies with clinical study                                      |
|----------------|--------------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------------------------------|
| csDMARDs       | 1. Antiinflammatory effect                                                                        |                   | Glioma, melanoma, multiple myeloma, lung cancer, pancreatic cancer, solid organ tumor, sarcoma |
| CQ/HCQ         | 1. Autophagy inhibition                                                                          | V                 | Non-small cell lung cancer, chronic myeloid leukemia                   |
|                | 2. Inhibition of the TLR9/ nuclear factor kappa B (NF-κB) signaling pathway                       |                   |                                                                       |
|                | 3. Inhibition of CXCL12/CXCR4 signaling                                                          |                   |                                                                       |
|                | 4. Interference with the p53 pathway,                                                            |                   |                                                                       |
|                | 5. Modulation of tumor microenvironment                                                          |                   |                                                                       |
| CsA            | 1. Modulation of MDR expression and membrane P-glycoprotein (P-gp)                               | V                 |                                                                       |
|                | 2. Inhibition of cytochrome P-450 enzyme system                                                  |                   |                                                                       |
|                | 3. Activation of caspase-3 and caspase-9                                                          |                   |                                                                       |
|                | 4. Inhibition of nuclear factor-κB (NF-κB) activation                                             |                   |                                                                       |
|                | 5. Inhibition of PI3 kinase–AKT1 signaling pathway                                               |                   |                                                                       |
|                | 6. Inhibition of Wnt/calcineurin/NF-AT pathway                                                    |                   |                                                                       |
| Leflunomide    | 1. Inhibition of the mitochondrial enzyme dihydroorotate dehydrogenase                            | V                 | Multiple myeloma                                                      |
|                | 2. Inhibition of the tyrosine kinase activity of platelet-derived growth factor receptors (PDGFR) and EGFR |                   |                                                                       |
| MTX            | 1. Inhibition of dihydrofolate reductase (DHFR)                                                   | V                 | Breast cancer, head and neck cancer, leukemia                         |
| MMF/MPA        | 1. Regulation of the de novo purine synthesis pathway via inhibiting the inosine monophosphate dehydrogenase (IMPDH) | V                 | Pancreatic cancer, lymphoma, multiple myeloma                         |
|                | 2. Suppression of the function of VEGF                                                           |                   |                                                                       |
| SSZ            | 1. Inhibition of the xc− cystine transporter                                                      | V                 | Gastric cancer, glioma, non-small cell lung cancer, urogenital cancer |
|                | 2. Inhibition of matrix metalloproteinase-related genes                                           |                   |                                                                       |
|                | 3. Increase in accumulation of intracellular ROS                                                  |                   |                                                                       |
|                | 4. Inhibition of nuclear factor-κB (NF-κB) activation                                             |                   |                                                                       |
propensity score matching, HCQ use did not increase the cancer risk in Taiwanese patients with autoimmune diseases [15].

Manic et al. and Verbaanderd et al. have carefully reviewed the efficacy of CQ and HCQ as antineoplastic agents. Beneficial effects of CQ or HCQ monotherapy administration were noted in a range of cancer types in in vivo studies. CQ or HCQ in combination with various anticancer agents, including chemotherapeutic drugs, tyrosine kinase inhibitors, various monoclonal antibodies, hormone therapies, and radiotherapy, also showed satisfying results in in vitro models. Recently, clinical trials investigating the response of CQ or HCQ in combination with other anticancer agents have been completed or are ongoing. Promising outcomes have been observed in patients with glioma and multiple myeloma treated with CQ in addition to other anticancer treatment. In patients with solid organ tumors, glioblastoma, lung cancer, multiple myeloma, pancreatic cancer, or sarcoma, combination therapies of HCQ and anticancer agents have also shown good results. The antineoplastic mechanism of CQ and HCQ may result from (1) autophagy inhibition, (2) inhibition of the TLR9/ nuclear factor kappa B (NF-κB) signaling pathway, (3) inhibition of CXCL12/CXCR4 signaling, (4) interference with the p53 pathway, and (5) modulation of tumor microenvironment. In short, CQ and HCQ improve the therapeutic effects of chemo-, radio-, and immunotherapeutic antineoplastic regimens in many different cancer types [16, 17].

**Colorectal Cancer**

Preclinical models showed that HCQ enhances the antineoplastic activity of vorinostat (VOR) in colorectal cancer (CRC) cells [18]. A cohort study of HCQ and VOR in patients with refractory metastatic CRC reported a survival outcome comparable to other treatment in metastatic CRC [19].

**Glioma**

Studies showed that adding CQ to conventional treatment may be beneficial for patients with glioblastoma multiforme (GBM). Improved survival outcomes have been observed in patients with adjuvant CQ treatment compared with controls [20, 21]. Nonetheless, a phase I/II clinical trial showed HCQ combined with radiotherapy (RT) and temozolomide (TMZ) in patients with GBM achieved no significant improvement in overall survival (OS), which might be related to inadequate autophagy inhibition [22].

**Melanoma**

Autophagy is found to be associated with melanoma cell survival. A preclinical study showed that autophagy inhibition with HCQ significantly augments TMZ cytotoxicity in melanoma cells [23]. A phase I trial reported that, among 29 evaluable patients with advanced solid tumors and melanoma, 3 had partial remission (PR) and 8 had stable disease (SD) on HCQ and dose-intense TMZ [24].

A preclinical study reported that HCQ has a synergistic antineoplastic effect when combined with the mTOR inhibitor temsirolimus (TEM) in melanoma cells [25]. A phase I trial demonstrated that, among 21 evaluable patients with advanced solid tumors and melanoma, 14 had SD on HCQ and TEM [26].

| Medication | Proposed antineoplastic mechanism | Preclinical study | Malignancies with clinical study |
|------------|----------------------------------|------------------|---------------------------------|
| Thiopurines | 1. Antiinflammatory effect | Colorectal cancer, multiple myeloma |
| csDMARDs conventional synthetic disease-modifying antirheumatic drugs, CQ chloroquine, CsA cyclosporine A, MMF mycophenolate mofetil, MPA mycophenolic acid, MTX methotrexate, SSZ sulphasalazine | | |
| Medication | Malignancy | Study design | OCEBM Levels of Evidence | Numbers of subject | Dose | Clinical report | Article |
|------------|------------|--------------|--------------------------|-------------------|------|-----------------|---------|
| CQ/HCQ    | Brain metastasis | RCT | Level 2 | 73 (CQ + whole-brain RT/whole-brain RT 39/34) | 150 mg/day | Treatment with CQ increased PFS of brain metastases (RR 0.31, 95% CI 0.1–0.9, P = 0.046) | Rojas-Puente et al., 2013 [140] |
|            |            | Cohort study | Level 3 | 20 | 250 mg/day | Among 16 evaluable patients with brain metastases treated with CQ and whole-brain RT, 2 had CR, 13 had PR and one had SD | Elledrdge, 2013 [141] |
| CQ/HCQ    | Glioma     | RCT | Level 2 | 18 (CQ/ctrl 9/9) | 150 mg/day | Significantly longer survival in patients with additional CQ treatment than in controls (33 ± 5 versus 11 ± 2 months; P = 0.0002) | Briceno, 2003 [142] |
| CQ/HCQ    | Glioma     | RCT | Level 2 | 30 (CQ/ctrl 15/15) | 150 mg/day | Adding CQ to conventional treatment improved median survival postoperatively in patients with GBM compared with controls (24 versus 11 months) | Socho, 2006 [20] |
| CQ/HCQ    | Case–control study | Level 4 | 123 (CQ/ctrl 41/82) | 150 mg/day | Improved survival in patients with GBM treated with adjuvant CQ (mean survival 25 ± 3.4 versus 11.4 ± 1.3 months; P = 0.000; OR 0.4, 95% CI 0.26–0.6) | Briceno, 2007 [21] |
| Melanoma   | Case series | Level 4 | 92 (phase I/II 16/76) | 200–800 mg/day | No significant improvement in overall survival was noted at the maximal tolerated dose of HCQ 600 mg/day | Rosenfeld, 2014 [32] |
| Melanoma   | Case series | Level 4 | 40 | 200–1200 mg/day | Among 29 evaluable patients with advanced solid tumors and melanoma, 3 had PR and 8 had SD on HCQ and dose-intense temozolomide | Rangwala, 2014 [24] |
| Melanoma   | Case series | Level 4 | 39 | 200–1200 mg/day | Among 21 evaluable patients with advanced solid tumors and melanoma, 14 had SD on HCQ and temsirolimus | Rangwala, 2014 [26] |
| Multiple myeloma | Case series | Level 4 | 22 | 100–1200 mg/day | Among the evaluable patients, three (14%) achieved PR, three (14%) had minor responses, and ten (45%) achieved SD | Vogl, 2014 [30] |
| Multiple myeloma | Case series | Level 4 | 3986 (HCQ/ctrl 1993/1993) | Not mentioned | HCQ did not increase the cancer risk in Taiwanese patients with autoimmune diseases | Mao, 2018 [15] |
| Non-small cell lung cancer | Case series | Level 4 | 27 (HCQ/HCQ + erlotinib 8/19) | 400–1000 mg/day | Among 19 patients on HCQ and erlotinib, 1 had PR and 4 had SD | Goldberg, 2012 [31] |
| Non-small cell lung cancer | Case series | Level 4 | 38 (phase Ib/II 8/30) | 400 mg/day | ORR of 33% to carboplatin, paclitaxel (and bevacizumab if eligible), and HCQ in 30 evaluable patients with metastatic NSCLC | Malhotra, 2019 [32] |
| Pancreatic cancer | Case series | Level 4 | 20 | 800 or 1200 mg/day | In patients with previously treated metastatic pancreatic cancer, minimal therapeutic efficacy of HCQ monotherapy was observed | Wolpin, 2014 [35] |
| Pancreatic cancer | Case series | Level 4 | 35 | 200–1200 mg/day | In patients with pancreatic adenocarcinoma, preoperative autophagy inhibition with HCQ plus gemcitabine was safe and effective | Boone, 2015 [143] |
### Table 2 continued

| Medication | Malignancy                | Study design | OCEBM Levels of Evidence | Numbers of subject | Dose         | Clinical report                                                                 | Article       |
|------------|---------------------------|--------------|--------------------------|--------------------|--------------|---------------------------------------------------------------------------------|---------------|
| RCT        | Level 2                    | 120 (HCQ + GA/GA 56/56) | 1200 mg/day              | ORR improvement was observed in the HCQ group (38.2% versus 21.1%; \(P = 0.047\)); however, OS showed no significant difference | Karasic, 2019 [36] |
| RCT        | Level 2                    | 64 (34/30 HCQ + GA/GA) | 1200 mg/day              | Zeh, 2020 [37]     |              |                                                                                 |               |
| Renal cell carcinoma | Case series | Level 4       | 33                       | 800–1200 mg/day    | In patients with RCC, 2 (6%) had PR and 20 had SD (61%) on everolimus and HCQ | Haa, 2019 [39] |
| Sarcoma    | Case series | Level 4       | 10                       | 400 mg/day         | In ten sarcoma patients treated with HCQ and rapamycin, six had PR and three had SD | Chi, 2015 [144] |
| Solid organ tumors | Cohort study | Level 3       | 25                       | 400 mg/day         | In patients with metastatic solid tumor on adjuvant rapamycin and HCQ with metronomic chemotherapy, an ORR of 40% and a disease control rate of 8-4% were observed | Chi, 2015 [44] |
| Case series | Level 4                  | 27           | 400–1000 mg/day          | Among 24 evaluable patients with advanced solid tumors treated with HCQ in combination with vorinostat, 1 had PR and 10 had SD | Mahalingam, 2014 [145] |
| CsA        | Colorectal cancer         | Case series | Level 4                  | 39                 | 4 mg/kg/day  | Among 39 patients with metastatic CRC, 2 had PR and 18 had SD, treated with the combination of oral selumetinib and CsA | Krishnamurthy, 2018 [55] |
| Chronic myeloid leukemia | Case series | Level 4      | 2                        | 250–400 mg/day     | CsA enhances the effect of dasatinib in Bcr-Abl+ leukemia, combination of dasatinib and CsA led to hematopoietic toxicity in two patients with CML | Gardner, 2014 [52] |
| Gastric cancer | Case series | Level 4      | 24                       | 10 mg/kg/week      | Among 24 patients with advanced gastric cancer on oral CsA and paclitaxel, 8 had PR and 11 had SD with an ORR of 33% (95% CI 18–52%) | Kruijtzer, 2003 [61] |
| Non-small cell lung cancer | Case series | Level 4      | 26                       | 10 mg/kg/week     | Oral paclitaxel and CsA had an ORR of 26% (95% CI 10–48%) in patients with advanced NSCLC | Kruijtzer, 2002 [62] |
| Leflunomide | Multiple myeloma          | Case series | Level 4                  | 11                 | 20–60 mg/day | In patients with relapsed/refractory multiple myeloma, 9 out of 11 achieved SD on leflunomide | Rosenzweig, 2020 [74] |
| Medication | Malignancy                  | Study design | OCEBM Levels of Evidence | Numbers of subject | Dose       | Clinical report                                                                 | Article       |
|------------|-----------------------------|--------------|--------------------------|--------------------|------------|---------------------------------------------------------------------------------|---------------|
| MTX        | Breast cancer               | Case series  | Level 4                  | 63                 | 10 mg/week | Among patients with metastatic breast cancer on oral MTX and cyclophosphamide, two had CR, ten had PR (ORR 19.0%, 95% CI 10.2–30.9%), and eight had SD | Colleoni, 2002 [81] |
|            |                              | Case series  | Level 4                  | 48                 | 10 mg/week | Among patients with metastatic breast cancer on oral MTX and cyclophosphamide, 1 patient achieved CR, 10 had PR, and 19 had SD   | Hussein, 2017 [82] |
|            | Head and neck cancer        | Non-RCT      | Level 3                  | 123 (oral MTX + RT/IV MTX + RT/RT 48/36/39) | 7.5 mg/day for 5 days | Patients with head and neck cancer on oral MTX prior to radiotherapy had better 3-year survival (33% versus 20% versus 10%, P = 0.04) and tumor regression | Lustig, 1976 [83] |
|            |                              | Cohort study | Level 3                  | 84                 | 15 mg/m²/week | Among patients with head and neck cancer treated with oral MTX and celecoxib, 9 (11%) patients had PR and 47 (56%) had SD | Harsh, 2020 [84] |
|            | Leukemia                    | RCT          | Level 2                  | 144 (oral/IM 75/39) | 20 mg/m²/week | In children with ALL, oral MTX is as effective as IM MTX                        | Chessells, 1987 [85] |
|            |                              | Case series  | Level 4                  | 10                 | 5–20 mg/week | Among patients with LGL leukemia, five achieved CR and one achieved PR          | Loughran, 1994 [90] |
|            |                              | Case series  | Level 4                  | 96                 | 150 mg/m² every 2 weeks | In children with ALL, low-dose methotrexate/mercaptopurine is effective and safe | Mahoney, 1995 [88] |
|            | Leukemia                    | RCT          | Level 2                  | 164 (IV + oral/oral 80/80) | 20 mg/m²/week | In children with ALL, oral MTX is as effective as oral + IV MTX                | Lange, 1996 [86] |
|            |                              | Case series  | Level 4                  | 239                | 100 mg/m²/week | In children with ALL, divided-dose oral MTX is effective                       | Winick, 1996 [87] |
|            | Leukemia                    | Non-RCT      | Level 3                  | 233 (MTX + 6-MP/LSA₂L₂ 135/98) | 20 mg/m²/week | In children with T-lineage or with higher-risk B-lineage, ALL oral MTX and mercaptopurine are effective as a maintenance therapy | Schmiegelow, 2009 [89] |
|            |                              | Case series  | Level 4                  | 24                 | 10 mg/m²/week | In patients with LGL leukemia, long-term single-agent oral MTX leads to longer responses compared with prednisolone | Munir, 2016 [91] |
| MMF/MPA    | Lymphoma                    | Cohort study | Level 3                  | 13,502 (MMF/ctrl 6751/6751) | Not mentioned | The risk of developing lymphoma and post-transplant lymphoproliferative disease in the MMF group was reduced | Robson, 2005 [97] |
| Multiple myeloma | Case series | Level 4         | 11                   | 1–5 g/day | PR in a patient (9%), SD in four patients (36%), and progressive disease in six patients | Takebe, 2004 [98] |
| Pancreatic cancer | Non-RCT | Level 3         | 18 (MMF/ctrl 12/6) | 1 or 2 g/day | In patients with resectable pancreatic cancer, no significant various expression of VEGF was noted in the MMF group | Rodrigues-Pascal, 2013 [99] |
| Medication | Malignancy          | Study design | OCEBM Levels of Evidence | Numbers of subject | Dose       | Clinical report                                                                                                                                                                                                 | Article |
|------------|---------------------|--------------|--------------------------|--------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| SSZ        | Colorectal cancer   | Cohort study | Level 3                  | 26 (long/short-term SSZ 13/13) | Not mentioned | In patients with UC-related cancer, long-term SSZ is suggested to suppress the differentiation and proliferation of CRC cells                                                                                      | Seishima, 2016 [117] |
|            |                     |              |                          |                    |            |                                                                                                                                                                                                              |         |
|            |                     |              |                          |                    |            |                                                                                                                                                                                                              |         |
| Gastric    |                     | Case series  | Level 4                  | 8                  | 8–12 g/day | In eight patients with CD44v9 advanced gastric cancer, 4 patients had reduced cancer cell population in post-SSZ treatment biopsy tissue                                                                                | Shitara, 2017 [120] |
|            |                     |              |                          |                    |            |                                                                                                                                                                                                              |         |
|            |                     | Case series  | Level 4                  | 7                  | 6 g/day    | Among seven patients with CD44v9 gastric cancer refractory to cisplatin, one patient achieved SD for more than 4 months on SSZ combined with cisplatin                                                              | Shitara, 2017 [121] |
|            |                     |              |                          |                    |            |                                                                                                                                                                                                              |         |
| Glioma     |                     | Case series  | Level 4                  | 10                 | 1.5–6 g/day | No clinical response or unbearable side effects were observed                                                                                                                                                    | Robe, 2009 [122] |
|            |                     |              |                          |                    |            |                                                                                                                                                                                                              |         |
| Non-RCT    |                     | Case series  | Level 4                  | 24 (sulfasalazine/ctrl 12/12) | 1–4 g/day  | Temozolomide and SSZ with RT had no antineoplastic activity in postoperative patients with newly diagnosed glioblastoma                                                                                       | Takeuchi, 2014 [123] |
|            |                     |              |                          |                    |            |                                                                                                                                                                                                              |         |
| Non-small cell lung cancer | Case series  | Level 4                  | 15              | 1.5–4.5 g/day | Among 15 patients with CD44v9 advanced NSCLC, 4 achieved PR (ORR 26.7%) and 7 achieved SD (46.7%) on SSZ in combination with cisplatin and pemetrexed                                                    | Otsubo, 2017 [124] |
|            |                     |              |                          |                    |            |                                                                                                                                                                                                              |         |
| Urogenital cancer | Case reports  | Level 4                  | 2                | Not mentioned | Impressive results were observed in two patients with advanced urogenital cancer treated with SSZ and anticancer therapies                                                                                     | Takayama, 2016 [126] |
| Thiopeurines| Colorectal cancer   | Cohort study | Level 3                  | 755                | 2 mg/kg/day | No significant decrease in the risk of colorectal neoplasia (OR 1.13, 95% CI 0.46–2.77)                                                                                                                   | Connell, 1994 [146] |
|            |                     |              |                          |                    |            |                                                                                                                                                                                                              |         |
|            |                     | Cohort study | Level 3                  | 98                 | Not mentioned | No significant decrease in the risk of colorectal neoplasia (RR 1.12, 95% CI 0.26–4.77)                                                                                                                     | Lashner, 1997 [147] |
|            |                     | Case–control study | Level 4                  | 59 (case/ctrl 26/33) | Not mentioned | No significant decrease in the risk of colorectal neoplasia (OR 0.68, 95% CI 0.17–2.6)                                                                                                                  | Tung, 2001 [148] |
|            |                     | Cohort study | Level 3                  | 2204               | Not mentioned | No significant decrease in the risk of colorectal neoplasia (OR 0.86, 95% CI 0.43–1.73)                                                                                                                     | Fraser, 2002 [149] |
|            |                     | Case–control study | Level 4                  | 204 (case/ctrl 68/136) | Not mentioned | No significant decrease in the risk of colorectal neoplasia (< 5-year use: OR 0.34 95% CI 0.09—1.25; > 5-year use: OR 0.73, 95% CI 0.30–1.78)                                                           | Rutter, 2004 [150] |
|            |                     | Cohort study | Level 3                  | 315                | Average dose 60.6 ± 19.5 mg/day | No significant decrease in the risk of colorectal neoplasia (HR 1.06, 95% CI 0.59–1.93)                                                                               | Matula, 2005 [151] |
|            |                     | Cohort study | Level 3                  | 723                | Not mentioned | No significant decrease in the risk of colorectal neoplasia (OR 1.57, 95% CI 0.19–12.4)                                                                                                           | Lakatos, 2006 [152] |
|            |                     | Case–control study | Level 4                  | 376 (case/ctrl 188/188) | average dose case/ctrl 1.0/1.3 mg/kg/day | No significant decrease in the risk of colorectal neoplasia (> 1-year use: OR 3.0, 95% CI 0.7–13.6)                                                          | Velazos, 2006 [153] |
|            |                     | Cohort study | Level 3                  | 418                | Not mentioned | No significant decrease in the risk of colorectal neoplasia (HR 1.0, 95% CI 0.6–1.6)                                                                                                                      | Gupta, 2007 [154] |
| Medication | Malignancy | Study design  | OCEBM Levels of Evidence | Numbers of subject | Dose | Clinical report | Article |
|------------|-----------|--------------|--------------------------|-------------------|------|----------------|---------|
| Case–control study | Level 4 | 15,441 (case/ctrl 392/15049) | Not mentioned | No significant decrease in the risk of colorectal neoplasia (OR 0.68, 95% CI 0.35–1.29) | Armstrong, 2010 [155] |
| Case–control study | Level 4 | 48 (case/ctrl 18/30) | Not mentioned | No significant decrease in the risk of colorectal neoplasia (OR 0.38, 95% CI 0.04–3.72) | Tang, 2010 [156] |
| Case–control study | Level 4 | 551 (case/ctrl 159/392) | Not mentioned | Statically significant decrease in the risk of colorectal neoplasia (OR 0.3, 95% CI 0.16–0.56) | Baars, 2011 [157] |
| Cohort study | Level 3 | 2578 | At least 50 mg/day | Statically significant decrease in the risk of colorectal neoplasia (OR 0.1, 95% CI 0.01–0.75) | van Schaik, 2011 [158] |
| Cohort study | Level 3 | 1084 | Not mentioned | No significant decrease in the risk of colorectal neoplasia (OR 0.27, 95% CI 0.02–4.53) | Setshed, 2011 [159] |
| Cohort study | Level 3 | 19,486 | Not mentioned | Statically significant decrease in the risk of colorectal neoplasia (HR 0.28, 95% CI 0.1–0.9) | Beaugerie, 2013 [160] |
| Cohort study | Level 3 | 812 | AZA 50–250 mg/day, 6-MP 25–150 mg/day | Statically significant decrease in the risk of colorectal neoplasia (OR 0.96, 95% CI 0.94–0.98) | Gómez-García, 2013 [161] |
| Cohort study | Level 3 | 43,969 | Not mentioned | No significant decrease in the risk of colorectal neoplasia (HR 1.00, 95% CI 0.61–1.63) | Pasternak, 2013 [162] |
| Case–control study | Level 4 | 434 (case/ctrl 59/141) | Not mentioned | Statically significant decrease in the risk of colorectal neoplasia (all: OR 0.28, 95% CI 0.12–0.65; < 2-year use: OR 0.19, 95% CI 0.05–0.70; > 2-year use: OR 0.27, 95% CI 0.09–1.78) | Rubin, 2013 [163] |
| Case–control study | Level 4 | 54 (case/ctrl 27/27) | Not mentioned | No significant decrease in the risk of colorectal neoplasia (OR 1.23, 95% CI 1.35–4.28) | Sachi, 2013 [164] |
| Case–control study | Level 4 | 553 (case/ctrl 183/370) | Not mentioned | Statically significant decrease in the risk of colorectal neoplasia (OR 0.31, 95% CI 0.19–0.53) | Nieminen, 2014 [165] |
| Case–control study | Level 4 | 831 (case/ctrl 45/786) | Not mentioned | Statically significant decrease in the risk of colorectal neoplasia (OR 0.21, 95% CI 0.06–0.74) | Gordillo, 2015 [166] |
| Case–control study | Level 4 | 3744 (case/ctrl 343/3401) | Not mentioned | No significant decrease in the risk of colorectal neoplasia (RR 0.99, 95% CI 0.75–1.31) | Kopylov, 2015 [167] |
| Cohort study | Level 3 | 434 | Not mentioned | No significant decrease in the risk of colorectal neoplasia (OR 0.7, 95% CI 0.1–3.3) | Nowacki, 2015 [168] |
| Case–control study | Level 4 | 202 (case/ctrl 29/173) | Not mentioned | Statically significant decrease in the risk of colorectal neoplasia (HR 0.30, 95% CI 0.13–0.70) | Navaneethan, 2016 [169] |
| Case–control study | Level 4 | 430 (case/ctrl 144/286) | Not mentioned | No significant decrease in the risk of colorectal neoplasia (OR 0.762, 95% CI 0.432–1.343) | Carrat, 2017 [170] |
**Multiple Myeloma**

Preclinical studies demonstrate that autophagy inhibition increases the antineoplastic activity of bortezomib in myeloma [27–29]. Therefore, the safety and efficacy of HCQ and bortezomib in patients with MM were studied in a phase I trial. Among 22 evaluable patients, 3 (14%) achieved PR, 3 (14%) had minor responses, and 10 (45%) achieved SD. The treatment was well tolerated and suggested to be a potential treatment option for patients with MM [30].

**Non-small Cell Lung Cancer**

A phase I trial showed an ORR of 5% (95% CI 1–25%) to HCQ and erlotinib in advanced non-small cell lung cancer (NSCLC) patients. In 19 patients on HCQ and erlotinib, 1 had PR for 20 months, which was longer than expected, and 4 had SD [31].

A phase I/II trial showed a higher objective response rate (ORR) was achieved by HCQ in combination with chemotherapy compared to chemotherapy alone. Furthermore, an even better result was reported in 9 patients with KRAS-positive NSCLC [32].

**Pancreatic Cancer**

Autophagy is related to pancreatic cancer growth and inhibitors of autophagy, such as CQ, may be helpful in pancreatic cancer treatment [33, 34]. HCQ monotherapy showed minimal therapeutic efficacy in patients with metastatic pancreatic cancer [35]. However, combined with gemcitabine and nab-paclitaxel (GA), HCQ improved the ORR in patients with advanced pancreatic cancer [36]. In addition, HCQ with GA leads to a better pathologic tumor response in patients with resectable pancreatic cancers [37]. Although the use of GA with HCQ is not routine practice, it may be beneficial as a neoadjuvant therapy for patients with locally advanced pancreatic cancer.

**Renal Cell Carcinoma**

A previous study showed mTOR inhibitor combined with HCQ causes synergistic cell death in renal cell carcinoma (RCC) cells [38]. In a phase I/II trial, everolimus, an mTOR inhibitor, and HCQ were administered to
patients with previously treated RCC. In 33 patients, two (6%) had PR, and 20 had SD (61%). Combined with everolimus, HCQ is safe and effective in patients with RCC [39].

**Solid Organ Tumors**

Preclinical studies showed that autophagy is related to the growth of solid organ tumors, such as bladder cancer [40, 41]. CQ and HCQ treatment leads to bladder cancer cell apoptosis [42] and growth suppression through the downregulation of matrix metalloproteinase-2 (MMP-2) by inhibiting autophagy [43].

In a small patient cohort study, HCQ and rapamycin were added to metronomic chemotherapy for patients with refractory metastatic solid tumors. In 24 evaluable patients with advanced solid tumors treated with HCQ in combination with vorinostat, one achieved PR and ten achieved SD [44].

**Cyclosporine A**

Cyclosporine A (CsA) is used for rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), severe atopic dermatitis, polymyositis, and dermatomyositis. It also has efficacy in preventing graft versus host disease and rejection in human organ transplantation. CsA has been reported to induce cancer progression and promote cancer cell growth [45], but recently antineoplastic activities of CsA were observed. CsA binds to cyclophilin, forming a complex that inhibits calcineurin and blocks the dephosphorylation of nuclear factor of activated T cells (NF-AT). Hence, the gene transcription of IL-2, IL-3, IFN-γ, and other factors are interfered, causing an immunosuppressive effect.

In vitro and in vivo studies have shown CsA may enhance the antineoplastic effect of chemotherapeutic agents and target therapeutic agents in different multidrug resistance malignancies. The antineoplastic property of CsA may act through (1) modulation of MDR expression and the membrane P-glycoprotein (P-gp), (2) inhibition of the cytochrome P-450 enzyme system [46], (3) activation of caspase-3 and caspase-9 [47–49], (4) inhibition of the NF-κB activation [50], (5) inhibition of the PI3 kinase-AKT1 signaling pathway [47] or (6) inhibition of the Wnt/calcineurin/NF-AT pathway [51–54].

**Colorectal Cancer**

Selumetinib is an oral MEK inhibitor, and it has been utilized as a treatment for patients with KRAS mutant CRC. However, limited clinical activity was observed and the resistance was found to be associated with the Wnt signaling pathway [54]. CsA, a Wnt/calcineurin/NF-AT signaling pathway modulator [51], is proposed to reverse the resistance of selumetinib in patients with CRC. To examine the hypothesis, a phase I/Ib trial investigated the efficacy of the combination of oral selumetinib and CsA in metastatic CRC patients. The combination of oral selumetinib and CsA was effective and well-tolerated. Totally, 39 patients were enrolled with two PR and 18 SD observed [55].

**Chronic Myeloid Leukemia**

CsA also plays a role in target therapy for Bcr-Abl+ chronic myeloid leukemia (CML). Dasatinib, a Bcr-Abl kinase inhibitor, is commonly used to treat Bcr-Abl+ CML. Wnt/Calcineurin/NF-AT signaling pathway, which is critical for the survival of Bcr-Abl+ leukemia cells, was inhibited by CsA. Targeting the pathway, CsA enhanced the sensitivity to Bcr-Abl kinase inhibitors in Bcr-Abl+ leukemia cells [51, 52]. A phase Ib trial demonstrated two CML patients treated with dasatinib and cyclosporine. Enhanced serum concentrations of dasatinib in patients were reported. However, more hematopoietic toxicity than expected was noted. Although the combination may be effective, the toxicity limits its use in clinical practice [52].

**Gastric Cancer**

Paclitaxel, a chemotherapeutic agent commonly used for advanced gastric cancer, is often administered by intravenous injection. Although oral paclitaxel is more convenient for long-term treatment schedules, low oral bioavailability due to drug efflux by the membrane P-gp in the gastrointestinal tract was
observed [56, 57]. Co-administration of oral CsA, acting as a P-gp inhibitor, significantly increased the bioavailability of oral paclitaxel [58–60]. A phase II trial enrolled 24 patients with advanced gastric cancer receiving the treatment of oral CsA and paclitaxel. Eight patients with PR, 11 with SD and an ORR of 33% (95% CI 18–52%) were observed [61]. The ORR was comparable with patients receiving intravenous paclitaxel therapy. Oral CsA and paclitaxel is an effective regimen in patients with advanced gastric cancer.

Non-small Cell Lung Cancer

A phase II trial showed that oral CsA and paclitaxel have efficacy in advanced NSCLC. Twenty-six patients received oral CsA and paclitaxel, and six patients achieved PR. The ORR was of the 23 assessable patients was 26% (95% CI 10–48%) with a median duration of 16 weeks. Furthermore, stabilization of the disease was noted in eight patients (35% of the assessable population) with a median duration of 17 weeks. The efficacy of oral CsA and paclitaxel was better than that of other drugs used in a single-agent setting. The safety profile of the treatment was also acceptable [62].

Leflunomide

Leflunomide has been approved for the treatment of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Leflunomide is converted to its active metabolite, teriflunomide, in the intestine and in the plasma. Leflunomide influences the de novo pyrimidine synthesis pathway via inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), leading to the arrest of cell growth [63]. Leflunomide also inhibits the tyrosine kinase activity of platelet-derived growth factor receptors (PDGFR) and epidermal growth factor receptor (EGFR), which are commonly expressed in tumor cells [63]. According to some preclinical studies, leflunomide showed antineoplastic activities in several malignancies, including prostate, breast, bladder, multiple myeloma, leukemia, and lymphoma [64–73].

Multiple Myeloma

A phase I trial demonstrated that patients with relapsed/refractory multiple myeloma (MM) were successfully treated by single-agent leflunomide. Twelve patients were enrolled in this study; one patient was not evaluable for response, and 9 out of 11 patients achieved SD on leflunomide. The safety profile showed that leflunomide is well tolerated up to a dosage of 60 mg/day with minimal toxicity [74].

Methotrexate

Methotrexate (MTX) is the first-line treatment for RA, PsA, and other forms of inflammatory arthritis. It is also effective for atopic dermatitis, dermatomyositis, SLE, and other autoimmune diseases. MTX has been known to suppress the inflammatory and immune response through an adenosine-mediated effect by inhibiting aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase [75, 76].

However, the use of MTX has been found to be associated with increased incidence of certain cancers, including melanoma, non-Hodgkin’s lymphoma, and lung cancer [77]. Despite the fact that MTX may be related to an elevated risk of cancer, antineoplastic effects of MTX have also been reported. Some studies suggest that MTX does not increase the risk of either noncutaneous or cutaneous malignancies [78, 79] or even might lower the risk of new-onset cancer [80]. For instance, high dose of MTX has been used for the treatment of malignancies, such as acute leukemia. Evidence showed that MTX blocks dihydrofolate reductase (DHFR), which converts dihydrofolate to tetrahydrofolate (THF), and results in the inhibition of cell proliferation [75, 76]. However, the dose of MTX used in treating cancer may be much higher than the dose used as a DMARD. Therefore, in our article, high-dose MTX (≥ 500 mg/m²) use is not discussed.

Breast Cancer

A clinical study showed a good outcome in treating patients with metastatic breast cancer with a combination of low-dose oral MTX and cyclophosphamide. Among 63 evaluable
patients, 2 patients achieved complete response (CR), 10 achieved PR (ORR 19.0%, 95% CI 10.2–30.9%), and 8 had SD [overall clinical benefit (CR + PR + SD > 24 weeks) = 31.7%, 95% CI 20.6–44.7%] [81]. A reduction in serum vascular endothelial growth factor (VEGF) levels was also noted and suggested to be related to the antineoplastic effect of this treatment [81].

Another phase II trial treating patients with metastatic breast cancer with metronomic chemotherapy in the form of low-dose oral MTX and cyclophosphamide showed similar results. Among 48 patients with metastatic breast cancer, 1 patient achieved CR and 10 had PR, while 19 patients had SD [82]. As a result, the combination of oral MTX and cyclophosphamide may be beneficial for patients with metastatic breast cancer.

**Head and Neck Cancer**

A clinical study showed that patients with head and neck cancer had better 3-year-survival (33% versus 20% versus 10%, P = 0.04) and tumor regression treated with oral MTX prior to RT compared with intravenous MTX prior to RT or RT alone [83].

A single-arm retrospective observational study included 84 patients with locally advanced, recurrent, and metastatic head and neck cancer treated with oral metronomic chemotherapy. Oral MTX and celecoxib were administered, and 9 (11%) patients had PR and 47 (56%) had SD [84]. Minimal toxicity and symptomatic relief were observed. Oral MTX and celecoxib may be effective and well tolerated in patients with head and neck cancer [84].

**Leukemia**

While parenteral administration of MTX, including intravenous and intrathecal, has long been used as treatment of leukemia, oral MTX was also utilized as a regimen of the consolidation therapy in children with lower-risk acute lymphoblastic leukemia (ALL). Evidence shows that it is as effective as parenteral MTX [85–88] and can be administered safely on an outpatient basis. Furthermore, the combination of oral MTX and mercaptopurine also showed benefits as a maintenance therapy in children with T-lineage or with higher-risk B-lineage ALL [89].

Oral MTX is also an effective treatment for patients with large granular lymphocyte (LGL) leukemia [90]. Long-term single-agent oral MTX leads to longer responses compared with prednisolone and has minimal toxicity [91].

**Mycophenolate Mofetil and Mycophenolic Acid**

Mycophenolate mofetil (MMF), a semisynthetic derivative of mycophenolic acid (MPA), regulates the de novo purine synthesis pathway via inhibiting the inosine monophosphate dehydrogenase (IMPDH). The de novo pathway is the main pathway of T- and B-lymphocyte purine synthesis [92]. Therefore, MMF and MPA have been known to inhibit the activities of T and B lymphocytes and lead to suppression of the immune system. Because of the immunosuppression effect, MMF has been used in patients with solid organ transplant for refractory rejection. MMF is also indicated for RA, inflammatory bowel disease (IBD), lupus erythematosus, pemphigus, and some other dermatologic disorders. In addition to their immunosuppression effect, MMF and MPA have been reported to be able to inhibit cancer cell proliferation and induce apoptosis in various solid organ tumors and hematological malignancies [93–96].

**Lymphoma**

A prospective observational cohort study investigated the association of long-term MMF use with the risk of malignancy in patients with renal transplant. Evidence shows that the risk of developing lymphoma and post-transplant lymphoproliferative disease in the MMF group was reduced compared with the non-MMF group. Additionally, a trend toward a lower risk of malignancy and a significant increase in time to malignancy were also reported [97].

**Multiple Myeloma**

In a phase I trial, 12 patients with progressive MM were on oral MMF twice daily up to a maximum dose of 5 g/day for 4 weeks. Oral
allopurinol 300 mg twice daily was also administered to inhibit the guanine salvage pathway. Among the 11 evaluable study patients, PR in 1 patient (9%), SD in 4 patients (36%), and progressive disease in 6 patients were reported. A significant positive correlation between MPA levels and a decrease in dGTP levels \( (P = 0.0001) \) was noted. The intracellular dGTP level had a statistically significant reduction in the PR/stable disease group compared with the progressive disease group [98]. Thus, the dGTP level may be useful as a biomarker to evaluate the efficacy of MMF in patients with MM.

**Pancreatic Cancer**
A preclinical and clinical study was performed to investigate the effects of MPA in pancreatic cancer. Growth inhibition and suppression were demonstrated in exposure of pancreatic cancer cells to MMF in vivo [99]. Then, 12 patients with resectable pancreatic cancer were treated with MMF (1 g/day in 6 patients and 2 g/day in the other 6) from 5 to 15 days prior to surgical resection. However, in the resected specimens, no significant various expression of VEGF was noted in the MMF-treated patients compared with the nontreated control patients [99].

**Sulfasalazine**
Sulfasalazine (SSZ) is an antiinflammatory drug indicated for patients with IBD, including ulcerative colitis (UC) and Crohn’s disease (CD), or rheumatoid arthritis. SSZ and its metabolites (sulfapyridine and 5-aminosalicylic acid) suppress lymphocyte activities and inhibit cytokine release. Preclinical studies showed that SSZ has an antineoplastic effect on lymphoma [100], breast cancer [101–105], colorectal cancer [106], gastric cancer [107], glioma [108–110], lung cancer [111], and prostate cancer. The mechanisms accounting for the antineoplastic effect of SSZ may include (a) inhibition of \( \text{xc}^- \) cystine transporter [100, 110–114], (b) inhibition of matrix metalloproteinase-related genes [102], (c) increasing the accumulation of intracellular reactive oxygen species (ROS) [102], and (d) inhibition of \( \text{NF-kB} \) activation [108]. However, the actual pharmacological effects of SSZ remain unclear.

**Colorectal Cancer**
A significantly higher risk of CRC was observed in patients with inflammatory bowel diseases (IBD), including UC and CD [115, 116]. The increased risk of carcinogenesis may be related to the chronic inflammation in the gastrointestinal tract. A retrospective review classified 26 patients with UC-related cancer into long-term (LT) \( (\geq 5 \text{ years}) \) and short-term (ST) \( (< 5 \text{ years}) \) SSZ treatment groups. Preferable immunohistochemical and pathological results were observed in the LT group. In conclusion, long-term SSZ is suggested to suppress the differentiation and proliferation of CRC cells [117].

**Gastric Cancer**
The expression of splice-variant isoforms of CD44 (CD44v) has been found in solid tumors, including some gastric cancer cell lines, presenting the characteristic of cancer stem cells [118]. CD44v interacts with \( \text{xCT} \), a subunit of the \( \text{xc}^- \) cystine transporter, and results in an increase of cystine uptake and enhancement of GSH synthesis. As a result, CD44v-positive cancer cells have properties of cancer stem cells and are resistant to ROS [118, 119]. SSZ, targeting the \( \text{xc}^- \) cystine transporter, is suggested to be an effective treatment for CD44v\(^{+}\) gastric cancer.

A maximum tolerated dose of 12 g/day of SSZ in patients with advanced gastric cancer was confirmed by a dose-escalation study. Furthermore, among eight patients with CD44v\(^{+}\) advanced gastric cancer, four patients had reduced cancer cell population in the post-treatment biopsy tissues after SSZ treatment [120]. Another phase I trial evaluated the efficacy of SSZ combined with cisplatin in patients with CD44v\(^{+}\) advanced gastric cancer refractory to cisplatin. Among seven patients enrolled in the study, one patient achieved SD for more than 4 months [121].
Glioma
Preclinical studies showed a strong antineoplastic activity of SSZ in malignant glioma cells. Therefore, a phase I/II trial was conducted investigating sulfasalazine for recurrent WHO grade 3 and 4 astrocytic gliomas in adults. However, no clinical response or unbearable side effects were observed among the ten patients enrolled in the study [122].

Another clinical study reported that temozolomide and SSZ with radiation therapy have no antineoplastic activity in postoperative patients with newly diagnosed glioblastoma. Progression-free survival (PFS) and OS did not differ between the SSZ and control group. Seizure-free survival was longer in the SSZ group, but no significant difference was noted compared with the control group [123]. Although antineoplastic activities of SSZ were noted in preclinical studies, further studies are needed to prove its benefit in patients with glioblastoma.

Non-small Cell Lung Cancer
A phase I trial administered SSZ in combination with cisplatin and pemetrexed in patients with CD44v$^+$ advanced NSCLC. Among 15 patients enrolled, 4 of them achieved PR (ORR 26.7%) and 7 achieved SD (46.7%). In addition, an 11.7-month median PFS longer than that of patients treated with cisplatin–pemetrexed alone in previous studies was also observed [124].

Urogenital Cancer
Preclinical studies showed that SSZ has antineoplastic effects against prostate cancer due to the inhibition of the $\text{xc}^-$ cystine transporter[113, 114, 125]. Case reports have demonstrated that SSZ has clinical benefit in patients with advanced urogenital cancer. Two patients, one with metastatic urinary bladder cancer and the other with castration-resistant prostate cancer, are both diagnosed with RA and receiving SSZ. Immunostaining prior to SSZ treatment showed CD44v$^+$ cells in both tumors. Despite the poor prognosis of metastatic urinary bladder cancer, the patient achieved CR after a series of chemotherapy, RT, and surgeries, and no CD44v$^+$ cells were noted in the metastatic lymph nodes or brain metastatic tumor. The other patient with castration-resistant prostate cancer had poor response to chemotherapy. However, during regular carboplatin chemotherapy, significant PSA decrease was observed following the initiation of SSZ in just 2 weeks. According to the impressive results in these two patients, SSZ was suggested to be able to sensitize advanced urogenital cancer to chemotherapy and RT [126].

Thiopurines (Azathioprine/6-Mercaptopurine/ 6-Thioguanine)
Thiopurines, including azathioprine (AZA) and its analog, 6-mercaptopurine (6-MP), are purine antimetabolites. They act through their major metabolite, 6-thioguanine (6-TG), which suppresses immune response in human by interfering with purine nucleic acid metabolism. Owing to the immunosuppressive properties of AZA/6-MP, they are commonly used to treat IBD, including UC and CD. AZA/6-MP also brings benefit in maintaining renal allografts [127, 128]. While long-term use of thiopurines may have potential carcinogenicity [129] and increase the risk of lymphoma [130], anticancer effects of thiopurines have also been reported lately. Also, the malignancy risk of azathioprine was mainly observed in patients with IBD and transplantation. The malignancy risk in patients with atopic dermatitis has been questioned [131].

Colorectal Cancer
The relationship between colorectal dysplasia and thiopurines in patients with IBD is still not clarified. Thiopurines are presumed to decrease the incidence of inflammation-related colorectal dysplasia because of their antiinflammatory effects. Gong et al. have carefully reviewed the antineoplastic effects of thiopurines (AZA/6-MP) against colorectal neoplasia in patients with IBD. Nine case–control and ten cohort studies were selected. Statistically, thiopurines significantly decreased the incidence of colorectal neoplasm in patients with IBD [summary relative risk (RR) 0.71, 95% CI 0.54–0.94, $P = 0.017$]. A tendency to reduce advanced
neoplasia was also noticed [132]. However, Jess et al. came to a different conclusion in their meta-analysis. Reviewing seven cohort studies and eight case–control studies, no significant decrease in the risk of colorectal neoplasia in patients with IBD on thiopurine treatment was observed [pooled odds ratios (OR) = 0.87, 95% CI 0.71–1.06] [133]. Because of the conflicting results of previous researches, another meta-analysis was performed by Zhu et al. to evaluate the protective effects of thiopurines. Eleven cohort and 16 case–control studies were included. The use of thiopurines reduced the risk of colorectal neoplasia both in case–control (OR 0.49, 95% CI 0.34–0.70) and cohort studies (RR 0.96, 95% CI 0.94–0.98). A protective effect of thiopurines against advanced neoplasia and colorectal cancer was also reported. The results indicated that thiopurines have a chemopreventive effect on colorectal neoplasms in patients with IBD [134]. Although some studies have shown a tendency toward a protective effect of thiopurines, the exact efficacy is still not well established and further investigations are suggested.

Multiple Myeloma

Previous research has suggested that AZA, an immunosuppressive agent, may have antitumor activity in the immune system. Thus, AZA was chosen as one of the regimens to treat MM in several clinical trials. A randomized controlled study demonstrated that 23.1% of patients with MM on AZA as a primary agent (6 out of 26) achieved remission. Though the response rate of AZA was significantly lower than that of melphalan and chlorambucil (59.3% and 30.0% respectively, \( P = 0.046 \)), some effects of AZA against MM were still observed [135]. In addition, patients receiving AZA combined with other regimens as a maintenance treatment had similar outcomes compared with those receiving other chemotherapy regimens [136, 137].

DISCUSSION

In this review, we summarize the antineoplastic activity, including possible mechanisms and efficacy, of csDMARDs against different malignancies. The antineoplastic mechanisms of csDMARDs are often distinct from their immunomodulatory pathway. A synopsis of mechanisms regarding antineoplastic activities is presented in Table 1. Included studies and evidence level based on Oxford Centre for EBM (OCEBM) are summarized in Table 2.

Nowadays, the role of csDMARDs in the treatment of immune-mediated inflammatory diseases has been gradually replaced by bDMARDs. However, csDMARDs still constitute the cornerstone in the treatment of these diseases. In addition to their antiinflammatory effects, many DMARDs, especially CQ/HCQ and MTX, have established antineoplastic effects. Although the antineoplastic activity of csDMARDs is based on preclinical or small-scale controlled studies in most cases, the potential to improve the outcome of cancer treatment deserves further investigation. Furthermore, csDMARDs combined with chemotherapy or target therapy may be beneficial in patients with cancer with multiple drug resistance to chemotherapeutic agents. The side effect of increased malignancy risk was the least acceptable to those patients who are receiving treatments for autoimmune disease [138, 139]. Therefore, knowing that csDMARDs have antineoplastic potential may improve drug adherence in these patients. Besides, knowledge of the antineoplastic potential of csDMARDs may guide physicians in the choice of csDMARDs for patients with established malignancies.

LIMITATIONS

Currently, the antineoplastic activity of csDMARDs is mostly observed in preclinical or small-scale controlled studies. Further studies are still needed to draw conclusions because the mechanism, efficacy, and safety of most csDMARDs used in treating patients with cancer are still inadequately studied.

CONCLUSIONS

Although biologics have been increasingly used for the treatment of inflammatory diseases, their risk of malignancies is still not fully
assessed. In contrast, the antineoplastic activity of csDMARDs has been reported in preclinical researches, case series, case-control studies, cohort studies, and randomized clinical trials. For patients with coexisting immune-based diseases and malignancy, csDMARDs could be the treatment of choice in certain cases. Nonetheless, the evidence supporting the use of csDMARDs to treat cancer remains limited, and further studies are encouraged.

ACKNOWLEDGEMENTS

Funding. The authors received no financial support for the research, authorship, and/or publication of this article.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author contributions. All authors contributed to the study conception and design. Literature search and analysis were performed by Cho-Hsun Hsieh, Yi-Wei Huang, and Tsen-Fang Tsai. The first draft of the manuscript was written by Cho-Hsun Hsieh, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Disclosures. Prof. Tsen-Fang Tsai has received honoraria or consultation fee from Abbvie, Allergan, Boehringer Ingelheim, Celgene, Eli-Lilly, GSK, Janssen, Novartis, and Pfizer. Cho-Hsun Hsieh has nothing to disclose. Yi-Wei Huang has nothing to disclose.

Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Data Availability. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. This article is based on previously conducted studies. Search strategies are specified in “Methods.”

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Harrison TR, Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, et al. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, et al., Harrison's principles of internal medicine. 19th ed. New York: McGraw Hill Education; 2015.

2. Katzung BG. Basic & clinical pharmacology. In: Katzung BG (eds) MD, PhD, Professor Emeritus, Department of Cellular & Molecular Pharmacology, University of California, San Francisco. Fourteenth Edition. ed. New York: McGraw-Hill; 2018.

3. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;384(6):316–26.

4. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40–6.
5. Wilton KM, Matteson EL. Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. Rheumatol Ther. 2017;4(2):333–47.

6. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004;77(12):1777–82.

7. Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum. 1997;26(6):794–804.

8. Hashimoto A, Chiba N, Tsuno H, Komiya A, Furukawa H, Matsui T, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42(4):564–71.

9. Tseng HW, Huang WC, Lu LY. The influence of immunosuppressants on the non-melanoma skin cancer among patients with systemic lupus erythematosus and primary Sjögren’s syndrome: a nationwide retrospective case-control study in Taiwan. Clin Exp Rheumatol. 2019;37(6):946–52.

10. Tseng HW, Lu LY, Lam HC, Tsai KW, Huang WC, Shiuie YL. The influence of disease-modifying anti-rheumatic drugs and corticosteroids on the association between rheumatoid arthritis and skin cancer: a nationwide retrospective case-control study in Taiwan. Clin Exp Rheumatol. 2018;36(3):471–8.

11. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.

12. Chi C-C. Evidence-based dermatology. Dermatol Sin. 2013;31(1):2–6.

13. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–42.

14. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17(4):654–66.

15. Mao IC, Lin CY, Wu CL, Kor CT, Chang CC. Hydroxychloroquine and risk of development of cancers: a nationwide population-based cohort study. Ther Clin Risk Manag. 2018;14:1435–43.

16. Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 2014;1(1):e29911.

17. Verbaander C, Maes H, Schaaf MB, Sukhatme VP, Pantziarka P, Sukhatme V, et al. Repurposing drugs in oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicine. 2017;11:781.

18. Carew JS, Medina EC, Esquivel JA 2nd, Mahalingam D, Swords R, Kelly K, et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med. 2010;14(10):2448–59.

19. Patel S, Hurez V, Nawrocki ST, Goros M, Michalek J, Sarantopoulos J, et al. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. Oncotarget. 2016;7(37):59087–97.

20. Sotelo J, Briceño E, López-González MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144(5):337–43.

21. Briceño E, Calderon A, Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol. 2007;67(4):388–91.

22. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem SR, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014;10(8):1359–68.

23. Ma XH, Piao S, Wang D, McAfee QW, Nathanson KL, Lum JJ, et al. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res. 2011;17(10):3478–89.

24. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014;10(8):1369–79.

25. Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS ONE. 2013;8(1):e55096.

26. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, et al. Combined mTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 2014;10(8):1391–402.

27. Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH. Preventing the autophagic survival response by inhibition of calpain.
enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemother Pharmacol. 2013;71(6):1567–76.

28. Kawaguchi T, Miyazawa K, Moriya S, Ohtomo T, Che XF, Naito M, et al. Combined treatment with bortezomib plus baflomycin A1 enhances the cytoidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. Int J Oncol. 2011;38(3):643–54.

29. Shen JPYC, Divakaran S, Ponduru S, Vogl DT, Amaravadi RK, Bradner JE. The rationale for combined proteasome and autophagy inhibition in multiple myeloma established us. Blood. 2008;112(11):2755.

30. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, et al. Combined autophagy and proteasome inhibition: a phase I trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 2014;10(8):1380–90.

31. Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, et al. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012;7(10):1602–8.

32. Malhotra J, Jabbour S, Orlick M, Riedlinger G, Guo Y, White E, et al. Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). Cancer Treat Res Commun. 2019;21:100158.

33. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25(7):717–29.

34. Bryant KL, Stalnecker CA, Zeitouni D, Klop J, Peng S, Tikunov AP, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019;25(4):628–40.

35. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014;19(6):637–8.

36. Karasie TB, O’Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, et al. Effect of gemicitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5(7):993–8.
involvement of the PI-3 kinase-AKT 1 pathway. Br J Cancer. 2003;88(6):973–80.

48. Sato M, Tsujino I, Fukunaga M, Mizumura K, Gon Y, Takahashi N, et al. Cyclosporine A induces apoptosis of human lung adenocarcinoma cells via caspase-dependent pathway. Anticancer Res. 2011;31(6):2129–34.

49. Zupanska A, Dziembowska M, Ellert-Miklaszewska A, Gaweda-Walerych K, Kaminska B. Cyclosporine A induces growth arrest or programmed cell death of human glioma cells. Neurochem Int. 2005;47(6):430–41.

50. Nakahara C, Nakamura K, Yamanaka N, Baba E, Wada M, Matsunaga H, et al. Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in human gastric carcinoma cells. Clin Cancer Res. 2003;9(14):5409–16.

51. Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O’Hare T, et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 2010;18(1):74–87.

52. Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, et al. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Am J Hematol. 2014;89(9):896–903.

53. Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E, et al. NFATc2 is a potential therapeutic target in human melanoma. J Invest Dermatol. 2012;132(11):2652–60.

54. Sprefacio A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res. 2013;19(15):4149–62.

55. Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, et al. Phase Ib results of the rational combination of selumetinib and cyclosporin A in advanced solid tumors with an expansion cohort in metastatic colorectal cancer. Cancer Res. 2018;78(18):5398–407.

56. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94(5):2031–5.

57. Malingrè MM, Beijnen JH, Schellens JH. Oral delivery of taxanes. Invest New Drugs. 2001;19(2):155–62.

58. van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res. 1998;4(10):2293–7.

59. Meerum Terwogt JM, Malingrè MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 1999;5(11):3379–84.

60. Malingrè MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, et al. The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anticancer Drugs. 2001;12(4):351–8.

61. Kruitjzer CM, Boot H, Beijnen JH, Locs HL, Parnis FX, Planting AS, et al. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol. 2003;14(2):197–204.

62. Kruitjzer CM, Schellens JH, Mezger J, Scheuleen ME, Keilholz U, Beijnen JH, et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2002;20(23):4508–16.

63. Zhang C, Chu M. Leflunomide: a promising drug with good antitumor potential. Biochem Biophys Res Commun. 2018;496(2):726–30.

64. Alamri RD, Elmeligy MA, Albalawi GA, Alquayr SM, Alsubhi SS, El-Ghaiesh SH. Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: a comprehensive review. Int Immunopharmacol. 2021;93:107398.

65. Hail N Jr, Chen P, Bushman LR. Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. Neoplasia. 2010;12(6):464–75.

66. Ozturk S, Mathur D, Zhou RW, Mulholland D, Parsons R. Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):718–23.

67. Humphries BA, Cutter AC, Buschhaus JM, Chen YC, Qyllt T, Palagama DSW, et al. Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer. Breast Cancer Res. 2020;22(1):60.
68. Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov. 2017;7(4):391–9.

69. Baumann P, Mandl-Weber S, Völkl A, Adam C, Bumeder I, Oduncu F, et al. Dihydropyrimidinase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther. 2009;8(2):366–75.

70. Buettrner R, Morales C, Caserta E, Troade E, Gunes EG, Viola D, et al. Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. Blood Adv. 2019;3(7):1027–32.

71. Dietrich S, Kraemer OH, Hahn E, Schafer C, Giese T, Hess M, et al. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. Clin Cancer Res. 2012;18(2):417–31.

72. Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia. 2008;22(3):635–8.

73. Leger DY, Liagre B, Beneytout JL. Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents. Apoptosis. 2006;11(10):1747–60.

74. Rosenzweig M, Palmer J, Tsai NC, Synold T, Wu X, Tao S, et al. Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase I study. Leuk Lymphoma. 2020;61(7):1669–77.

75. Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145–54.

76. Koz´min´ski P, Halik PK, Chesori R, Gniazdowska E. Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. Int J Mol Sci. 2020;21:10.

77. Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008;59(6):794–9.

78. Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica. 1983;167(5):260–1.

79. Stern RS, Zierler S, Parrish JA. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer. 1982;50(5):869–72.

80. Perng WT, Hung YM, Chang R, Lin CL, Chiou JY, Chen HH, et al. Methotrexate at middle and high accumulative doses might be associated with lower risk of new-onset cancers in patients with rheumatoid arthritis: a nationwide population-based cohort study. Ther Adv Musculoskelet Dis. 2020;12:21.

81. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13(1):73–80.

82. Hussein MM, Gaafar RM, Abdel-Warith AM, Ahmed WA, Allahloubi NMA, Salem SE, et al. Efficacy and toxicity of metronomic chemotherapy in metastatic breast cancer: Egyptian experience. Clin Breast Cancer. 2017;17(8):618–28.

83. Lustig RA, DeMare PA, Kramer S. Adjuvant methotrexate in the radiotherapeutic management of advanced tumors of the head and neck. Cancer. 1976;37(6):2703–8.

84. Harsh KK, Maharia SR, Nizhan RK, Khatri P, Beniwal S, Kumar HS, et al. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: a single-arm, retrospective study of a regional cancer center of North India (Asia). J Cancer Res Ther. 2020;16(3):559–64.

85. Chessells JM, Leiper AD, Tiedemann K, Hardisty RM, Richards S. Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. Arch Dis Child. 1987;62(2):172–6.

86. Lange BJ, Blatt J, Sather HN, Meadows AT. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukaemia: a Childrens Cancer Group study. Med Pediatr Oncol. 1996;27(1):15–20.

87. Winick N, Shuster JJ, Bowman WP, Borowitz M, Farrow A, Jacaruso D, et al. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukaemia. J Clin Oncol. 1996;14(10):2803–11.

88. Mahoney DH Jr, Camitta BM, Leventhal BG, Shuster JJ, Civin CJ, Ganin DJ, et al. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Cancer. 1995;75(10):2623–31.

89. Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthoj S, Vettenranta K, et al. Oral
methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. J Pediatr Hematol Oncol. 2009;31(6):385–92.

90. Loughran TP Jr, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood. 1994;84(7):2164–70.

91. Munir T, Bishton MJ, Carter I, McMillan A, O'Connor S, Sovani V, et al. Single-center series of bone marrow biopsy-defined large granular lymphocyte leukemia: high rates of sustained response to oral methotrexate. Clin Lymphoma Myeloma Leuk. 2016;16(12):705–12.

92. Naffouje R, Grover P, Yu H, Sendilnathan A, Wolfe K, Majd N, et al. Anti-tumor potential of IMP dehydrogenase inhibitors: a century-long story. Cancers (Basel). 2019;11:9.

93. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer. 1994;57(4):568–73.

94. Heits N, Heinte Z, Bernsmeier A, Kerber J, Hauser C, Becker T, et al. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts. BMC Cancer. 2016;20(16):322.

95. Guidicelli G, Chaingne-Delalande B, Dilhuydy MS, Pinson B, Mahfouf W, Pasquet JM, et al. The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells. PLoS ONE. 2009;4(5):e5493.

96. Takebe N, Cheng X, Fandy TE, Srivastava RK, Wu S, Shankar S, et al. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther. 2006;5(2):457–66.

97. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005;5(2):2954–60.

98. Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, et al. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res. 2004;10(24):8301–8.

99. Rodriguez-Pascual J, Sha P, García-García E, Rajeshkumar NV, De Vicente E, Quijano Y, et al. A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer. Invest New Drugs. 2013;31(1):14–9.

100. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia. 2001;15(10):1633–40.

101. Yu H, Yang C, Jian L, Guo S, Chen R, Li K, et al. Sulfasalazine-induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor. Oncol Rep. 2019;42(2):826–38.

102. Yu H, Hu K, Zhang T, Ren H. Identification of target genes related to sulfasalazine in triple-negative breast cancer through network pharmacology. Med Sci Monit. 2020;14(26):e926550.

103. Wei CW, YuYL, Lu JY, Hung YT, Liu HC, Yang GT. Anti-cancer effects of sulfasalazine and vitamin E succinate in MDA-MB 231 triple-negative breast cancer cells. Int J Med Sci. 2019;16(4):494–500.

104. Hong SE, Kim MR, Jang SK, Seong MK, Kim HA, Noh WC, et al. Hypoxia suppresses cysteine deprivation-induced cell death Via ATF4 regulation in MDA-MB-231 breast cancer cells. Anticancer Res. 2020;40(3):1387–94.

105. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of doxorubicin. Chemotherapy. 2007;53(3):210–7.

106. Ma MZ, Chen G, Wang P, Lu WH, Zhu CF, Song M, et al. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. Cancer Lett. 2015;368(1):88–96.

107. Miyoshi S, Tsugawa H, Matsuzaki J, Hirata K, Mori H, Saya H, et al. Inhibiting xCT improves 5-fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression. Anticancer Res. 2018;38(11):6163–70.

108. Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, et al. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res. 2004;10(16):5935–603.

109. Robe PA, Nguyen-Khac MT, Lambert F, Lechanteur C, JoloiS, Ernst-Gengoux P, et al. Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007;30(1):283–90.

110. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, et al. Inhibition of cystine
uptake disrupts the growth of primary brain tumors. J Neurosci. 2005;25(31):7101–10.

111. Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, et al. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol. 2009;64(3):463–72.

112. Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280–96.

113. Zheng Z, Luo G, Shi X, Long Y, Shen W, Li Z, et al. The X(c)- inhibitor sulfasalazine improves the anti-cancer effect of pharmacological vitamin C in prostate cancer cells via a glutathione-dependent mechanism. Cell Oncol (Dordr). 2020;43(1):95–106.

114. Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 2007;67(2):162–71.

115. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–35.

116. Wan Q, Zhao R, Xia L, Wu Y, Zhou Y, Wang Y, et al. Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: a meta-analysis of 26 observational studies. J Cancer Res Clin Oncol. 2021;147(4):1077–87.

117. Seishima R, Okabayashi K, Nagano O, Hasegawa H, Tsuruta M, Shimoda M, et al. Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer. Clin Res Hepatol Gastroenterol. 2016;40(4):487–93.

118. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400.

119. Wada T, Ishimoto T, Seishima R, Tsuchihashi K, Yoshihara M, Oshima H, et al. Functional role of CD44v-xCT system in the development of spasmyolytic polypeptide-expressing metaplasia. Cancer Sci. 2013;104(10):1323–9.

120. Shitara K, Doi T, Nagano O, Imamura CK, Ozeki T, Ishii Y, et al. Dose-escalation study for the targeting of CD44v(+) cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). Gastric Cancer. 2017;20(2):341–9.

121. Shitara K, Doi T, Nagano O, Fukutani M, Hasegawa H, Nomura S, et al. Phase I study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407). Gastric Cancer. 2017;20(6):1004–9.

122. Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, et al. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer. 2009;9(19):372.

123. Takeuchi S, Wada K, Nagatani K, Otani N, Osada H, Nawashiro H. Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma. Neurol India. 2014;62(1):42–7.

124. Ootsu K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, et al. Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. Cancer Sci. 2017;108(9):1843–9.

125. Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE, et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res. 2014;20(7):1990–2000.

126. Takayama T, Kubo T, Morikawa A, Morita T, Nagano O, Saya H. Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer. Med Oncol. 2016;33(5):45.

127. Dervieux T, Méard Y, Baudouin V, Maisin A, Zhang D, Broly F, et al. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. Br J Clin Pharmacol. 1999;48(6):793–800.

128. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation. 1992;53(5):1051–6.

129. Nguyen T, Vacek PM, O’Neill P, Colletti RB, Finette BA. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res. 2009;69(17):7004–12.

130. Khan N, Abbas AM, Lichtenstein GR, Loftus EV Jr, Bazzano LA. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007-15.e3.

131. Hughes R, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol. 2008;33(6):710–1.
patients with inflammatory bowel diseases: a meta-analysis. PLoS ONE. 2013;8(11):e81487.

133. Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12(11):1793-800.e1.

134. Zhu Z, Mei Z, Guo Y, Wang G, Wu T, Cui X, et al. Reduced risk of inflammatory bowel disease-associated colorectal neoplasia with use of thiopurines: a systematic review and meta-analysis. J Crohns Colitis. 2018;12(5):546–58.

135. Treatment of myeloma. Comparison of melphalan, chlorambucil, and azathioprine. Arch Intern Med. 1975;135(1):157–62.

136. Alexanian R, Salmon S, Bonnet J, Gehan E, Haut A, Weick J. Combination therapy for multiple myeloma. Cancer. 1977;40(6):2765–71.

137. Cohen HJ, Bartolucci AA, Forman WB, Silberman HR. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. J Clin Oncol. 1986;4(6):888–99.

138. Fraenkel L, Bogardus S, Concato J, Felson D. Unwillingness of rheumatoid arthritis patients to risk adverse effects. Rheumatology (Oxford). 2002;41(3):253–61.

139. Taylor PC, Ancuta C, Nagy O, de la Vega MC, Gordeev A, Janková R, et al. Treatment satisfaction, patient preferences, and the impact of suboptimal disease control in a large international rheumatoid arthritis cohort: SENSE study. Patient Prefer Adherence. 2021;15:359–73.

140. Rojas-Puentes LL, Gonzalez-Pinedo M, Crismatt A, Ortega-Gomez A, Gamboa-Vignolle C, Nuñez-Gomez R, et al. Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases. Radiat Oncol. 2013;8(8):209.

141. Eldredge HB, Denittis A, Duhadaway JB, Chernick M, Metz R, Prendergast GC. Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial. J Radiat Oncol. 2013;2:3.

142. Bricen˜o E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus. 2003;14(2):e3.

143. Boone BA, Bahary N, Zureikat AH, Moser AJ, Nor- molle DP, Wu WC, et al. Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22(13):4402–10.

144. Chi MS, Lee CY, Huang SC, Yang KL, Ko HL, Chen YK, et al. Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients. Onco-target. 2015;6(30):29808–17.

145. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxycamptothecin in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy. 2014;10(8):1403–14.

146. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343(8908):1249–52.

147. Lashner BA, Provencher KS, Seidner DL, Kneesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology. 1997;112(1):29–32.

148. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134(2):89–95.

149. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002;16(7):1225–32.

150. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451–9.

151. Matula S, Croog V, Itzkowitz S, Harpaz N, Bodian C, Hossain S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol. 2005;3(10):1015–21.

152. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006;12(3):205–11.

153. Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, et al. Predictive and protective factors associated with colorectal cancer in ulcerative
colitis: a case–control study. Gastroenterology. 2006;130(7):1941–9.

154. Gupta RB, Harpaz N, Itzkowitz S, Hoasain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133(4):1099–105.

155. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case–control study. Am J Gastroenterol. 2010;105(7):1604–9.

156. Tang J, Sharif O, Pai C, Silverman AL. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci. 2010;55(6):1696–703.

157. Baars JE, Looman CW, Steyerberg EW, Beukers R, Tan AC, Weusten BL, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case–control study. Am J Gastroenterol. 2011;106(2):319–28.

158. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut. 2012;61(2):235–40.

159. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol. 2012;27(2):385–9.

160. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145(1):166-75.e8.

161. Gómez-García M, Cabello-Tapia MJ, Sánchez-Capilla AD, De Teresa-Galván J, Redondo-Cerezo E. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada. Spain World J Gastroenterol. 2013;19(30):4877–86.

162. Pasternak B, Svanström H, Schmiegelow K, Jess T, Hvidt A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177(11):1296–305.

163. Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case–control study. Clin Gastroenterol Hepatol. 2013;11(12):1601–8.

164. Satchi M, Korelitz BI, Panagopoulos G, Bratcher J, Yu C, Atallah-Vinograd J, et al. Is treatment with 6-mercaptopurine for colitis associated with the development of colorectal cancer? Inflamm Bowel Dis. 2013;19(4):785–8.

165. Nieminen U, Jussila A, Nordling S, Mustonen H, Färkkilä MA. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case–control observational study based on registry data. Int J Cancer. 2014;134(1):189–96.

166. Gordillo J, Cabré E, Garcia-Planella E, Ricart E, Berrieto Y, Márquez L, et al. Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis data from the ENEIDA registry. J Crohns Colitis. 2015;9(12):1063–70.

167. Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study. Inflamm Bowel Dis. 2015;21(8):1847–53.

168. Nowacki TM, Brückner M, Eveslage M, Tepasse P, Pott F, Thoenissen NH, et al. The risk of colorectal cancer in patients with ulcerative colitis. Dig Dis Sci. 2015;60(2):492–501.

169. Navaneethan U, Rai T, Venkatesh PG, Kiran RP. Primary sclerosing cholangitis and the risk of colon neoplasia in patients with Crohn's colitis. Gastroenterol Rep (Oxf). 2016;4(3):226–31.

170. Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(4):533–41.